Supplemental Table 1. Comparison of baseline demographics and clinical parameters between the bleeding and non-bleeding groups.
| Total = 561 | Bleeding group (n = 21) | Non-bleeding group (n = 540) | P Value |
|---|---|---|---|
| Age, years | 68.8 ± 7.8 | 70.8 ± 10.8 | 0.41 |
| Male (%) | 17 (81.0) | 371 (69.2) | 0.25 |
| BMI, kg/m2 | 25.2 ± 3.5 | 23.9 ± 3.8 | 0.12 |
| Hypertension, n (%) | 18 (85.7) | 446 (83.4) | 0.53 |
| Dyslipidemia, n (%) | 18 (85.7) | 423 (79.4) | 0.35 |
| Diabetes, n (%) | 17 (81.0) | 259 (48.5) | 0.003 |
| CKD, n (%) | 10 (47.6) | 193 (36.1) | 0.28 |
| Current smoking, n (%) | 4 (19.0) | 70 (13.2) | 0.31 |
| Family history of IHD, n (%) | 3 (14.3) | 123 (23.3) | 0.24 |
| OMI, n (%) | 10 (47.6) | 174 (33.0) | 0.25 |
| CCB, n (%) | 11 (52.4) | 312 (59.8) | 0.50 |
| Use of β-Blocker, n (%) | 16 (76.2) | 299 (57.3) | 0.09 |
| Use of ARB/ACE-I, n (%) | 15 (71.4) | 322 (61.7) | 0.37 |
| Use of statins, n (%) | 18 (85.7) | 416 (79.7) | 0.36 |
| Use of aspirin, n (%) | 19 (90.5) | 497 (92.7) | 0.47 |
| Use of clopidogrel, n (%) | 13 (61.9) | 385 (71.8) | 0.32 |
| Use of prasugrel, n (%) | 4 (19.0) | 84 (15.7) | 0.43 |
| Other antiplatelet agents, n (%) | 2 (9.5) | 24 (4.5) | 0.26 |
| DOAC, n (%) | 3 (14.3) | 11 (2.1) | 0.01 |
| Warfarin, n (%) | 3 (14.3) | 40 (7.5) | 0.22 |
| EF (%) | 59.2 ± 9.3 | 60.1 ± 9.4 | 0.66 |
| Hb (g/dL) | 12.6 ± 1.7 | 13.1 ± 1.9 | 0.27 |
| Platelet count (103µL) | 208 ± 64.0 | 203.0 ± 57.3 | 0.73 |
| PT-INR | 1.25 ± 0.43 | 1.08 ± 0.29 | 0.10 |
| APTT(sec) | 34.6 ± 8.5 | 32.5 ± 9.4 | 0.11 |
Data are mean ± SD, or n (%).
See Table 1 for abbreviations.